Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Pia Burman

Physician

Default user image.

Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician’s questions

Author

  • Jacqueline Trouillas
  • Marie Lise Jaffrain-Rea
  • Alexandre Vasiljevic
  • Olaf Dekkers
  • Vera Popovic
  • Anne Wierinckx
  • Ann McCormack
  • Stephan Petersenn
  • Pia Burman
  • Gérald Raverot
  • Chiara Villa

Summary, in English

Pituitary adenohypophyseal tumors are considered as benign and termed “adenomas”. However, many tumors are invasive and a proportion of these exhibit an “aggressive behavior” with premature death due to progressive growth. Only very rare (0.2%) tumors with metastases are considered malignant and termed “carcinomas”. Taking into account this variability in behavior and the oncological definition, pathologists have proposed changing the term adenoma to tumor. Here we explain why use the term tumor instead of adenoma and identify tumor characteristics, associated with a high risk for poor prognosis. In a cohort of 125 tumors with aggressive behavior (APT) and 40 carcinomas with metastases (PC), clinical and pathological features were very similar. The comparison of this cohort (APT+PC) with a reference surgical cohort of 374 unselected patients clearly shows that the two cohorts differ greatly, especially the percentage of tumors with Ki67 ≥ 10% (35%vs3%; p < 0.001). A five-tiered prognostic classification, associating invasion and proliferation, identified grade 2b tumors (invasive and proliferative), with a high risk of recurrence/progression. Because half of the APT+ PC tumors have a Ki67 index ≥10%, and 80% of them show 2 or 3 positive markers of proliferation, we suggest that tumors that are clinically aggressive, invasive and highly proliferative with a Ki67 ≥ 10%, represent tumors with malignant potential. The percentage of grade 2b tumors, suspected of malignancy, which will become aggressive tumors or carcinomas is unknown. It is probably very low, but higher than 0.2% in surgical series. Early identification and active treatment of these aggressive tumors is needed to decrease morbidity and prolong survival.

Department/s

  • Genomics, Diabetes and Endocrinology

Publishing year

2020

Language

English

Pages

243-251

Publication/Series

Reviews in Endocrine and Metabolic Disorders

Volume

21

Issue

2

Document type

Journal article review

Publisher

Springer

Topic

  • Cancer and Oncology

Keywords

  • Aggressive pituitary adenoma
  • Aggressive pituitary tumor
  • Pituitary adenoma
  • Pituitary carcinoma
  • Pituitary tumor

Status

Published

Research group

  • Genomics, Diabetes and Endocrinology

ISBN/ISSN/Other

  • ISSN: 1389-9155